Top movers in Tuesday's session
By Mill Chart
Last update: Apr 9, 2024
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Today's top gainers
| Ticker | Change | Comment |
|---|---|---|
| ALLR | 2.0K% | Exciting news for ALLARITY THERAPEUTICS INC (NASDAQ:ALLR) as its stock price surged 2.0K% to $4.46 during Tuesday's session. The stock is trading 46.37% lower than a month ago. |
| LASE | 100.0% | LASER PHOTONICS CORP (NASDAQ:LASE) experienced a significant 100.0% increase, reaching $2.86 during Tuesday's session. A press release (Laser Photonics Secures Order From L3Harris Technologies for LaserTower Marking & Engraving System) was released earlier today. |
| MGAM | 98.0% | MOBILE GLOBAL ESPORTS INC's (NASDAQ:MGAM) shares rose 98.0% to $0.24. In the last month the share price dropped with 42.42%. |
| SLNA | 75.75% | SELINA HOSPITALITY PLC (NASDAQ:SLNA) experienced a significant 75.75% increase, reaching $0.07 during Tuesday's session. In the last month the stock lost 84.13%. |
| MDIA | 59.9% | MEDIACO HOLDING INC-CL A's (NASDAQ:MDIA) shares soared 59.9% to $4.83 during Tuesday's session. In the last month the share price increased with 491.0%. |
| CNXA | 44.95% | Investors witnessed a remarkable 44.95% rise in CONNEXA SPORTS TECHNOLOGIES's (NASDAQ:CNXA) shares, which climbed to $0.58 during Tuesday's session. In the last month the share price increased with 68.08%. |
| GPAK | 33.39% | GAMER PAKISTAN INC's (NASDAQ:GPAK) stock price is advancing with 33.39% to a price of $0.29. Shareholders saw the stock price going 35.16% lower in the past 3 months. |
| BSGM | 30.65% | With a 30.65% surge, BIOSIG TECHNOLOGIES INC's (NASDAQ:BSGM) stock price reached $1.62 during Tuesday's session, signaling positive momentum. Shareholders saw the stock price going 100.0% higher in the past month. |
| SYRS | 28.44% | SYROS PHARMACEUTICALS INC's (NASDAQ:SYRS) stock price increased by 28.44% to $5.78. A press release (Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression) was released earlier today. |
| IZM | 25.0% | ICZOOM GROUP INC -CLASS A's (NASDAQ:IZM) shares rose 25.0% to $29.0 during Tuesday's session. The stock is trading 151.0% higher than a month ago. |
For the full top gainers list go to our top gainers page.
Today's top losers
| Ticker | Change | Comment |
|---|---|---|
| VINC | -74.47% | VINCERX PHARMA INC's (NASDAQ:VINC) stock price encountered a 74.47% decline, reaching $1.22 during Tuesday's session. In the last month the share price dropped with 39.65%. |
| WAVE | -33.33% | Investors witnessed a 33.33% drop in ECO WAVE POWER GLOBAL AB-ADR's (NASDAQ:WAVE) stock price, which closed at $2.8 during Tuesday's session. In the last month the share price increased with 213.0%. |
| AZTR | -21.67% | Investors witnessed a 21.67% decrease in AZITRA INC's (NYSEARCA:AZTR) stock price, which closed at $0.17 during Tuesday's session. In the last 3 months the stock lost 81.5%. |
| HUBC | -21.64% | HUB CYBER SECURITY LTD's (NASDAQ:HUBC) stock price decreased by 21.64% to $1.05. Shareholders saw the stock price going 27.57% lower in the past 3 months. |
| WGSWW | -20.21% | GENEDX HOLDINGS CORP (NASDAQ:WGSWW) encountered a 20.21% decrease in its shares, reaching $0.03 during Tuesday's session. In the last month the stock lost 59.4%. |
| TLRY | -19.88% | The market experienced a downward movement in TILRAY BRANDS INC's (NASDAQ:TLRY) stock price, closing at $2.08 with a 19.88% decrease during Tuesday's session. The company's earnings where released Yesterday. Earlier today the company had a press release: Tilray Brands, Inc. Reports Q3 Fiscal 2024 Financial Results. |
| KA | -19.24% | KINETA INC's (NASDAQ:KA) shares fell 19.24% to $0.44 during Tuesday's session. Shareholders saw the stock price going 22.3% lower in the past month. |
| FCUV | -17.91% | Investors witnessed a 17.91% drop in FOCUS UNIVERSAL INC's (NASDAQ:FCUV) stock price, which closed at $0.29 during Tuesday's session. In the last 3 months the stock lost 76.69%. |
| CVKD | -16.96% | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) encountered a 16.96% decrease in its shares, reaching $0.42 during Tuesday's session. In the last month the stock lost 23.84%. |
| VVPR | -16.25% | The market experienced a 16.25% downturn in VIVOPOWER INTERNATIONAL PLC's (NASDAQ:VVPR) stock price, closing at $4.69 during Tuesday's session. A press release (VIVOPOWER ANNOUNCES FURTHER STRATEGIC DIRECT INVESTMENT IN TEMBO FROM EMIRATI INVESTMENT OFFICE) was released yesterday. |
To see the full list of top losers you can use our top losers page.
KINETA INC
NASDAQ:KA (5/6/2024, 10:20:28 AM)
0.5793
-0.01 (-1.8%)
KA News
17 days ago - ChartmillWhat's going on in today's pre-market sessionFriday's pre-market session: top gainers and losers
20 days ago - ChartmillStay updated with the stocks that are on the move in today's after-hours session.Tuesday's after hours session: top gainers and losers
20 days ago - ChartmillTuesday's session: top gainers and losersWondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
20 days ago - ChartmillHere are the top movers in Tuesday's session, showcasing the stocks with significant price changes.Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
2 months ago - BusinessInsiderKA Stock Earnings: Kineta Beats EPS for Q4 2023InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kineta (NASDAQ:KA) just reported results for the fourth quarter of 2023.Kineta ...
2 months ago - InvestorPlaceKA Stock Earnings: Kineta Beats EPS for Q4 2023KA stock results show that Kineta beat analyst estimates for earnings per share the fourth quarter of 2023.
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No...
